Results For "generics"

195 News Found

We expect to turn profitable in two years: M Satyendra (Satish), Managing Director, Athena Global Technologies & MedleyMed

interviews | February 09, 2022

We expect to turn profitable in two years: M Satyendra (Satish), Managing Director, Athena Global Technologies & MedleyMed

MedleyMed is present across the pharma and healthcare value chain. It offers digital solutions to all stake holders and is in the process of expanding its operations in India and USA. In an interview with Thomas C Thottathil, M Satyendra (Satish), Managing Director, Athena Global Technologies & MedleyMed discussed his plans and opportunities in India

Dr Reddy’s launch generic version of Vasostrict in the US

Drug Approval | February 09, 2022

Dr Reddy’s launch generic version of Vasostrict in the US

The Vasostrict brand market had U.S. sales of approximately US $ 878.5 million MAT for the most recent twelve months ending in December 2021 according to IQVIA Health

Sun Pharma demonstrates strong performance on all fronts: ICICI Direct

News | February 04, 2022

Sun Pharma demonstrates strong performance on all fronts: ICICI Direct

Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses

Dr. Reddy's set to acquire Nimbus Health

News | February 03, 2022

Dr. Reddy's set to acquire Nimbus Health

The acquisition will allow Dr. Reddy's to build on Nimbus Health's strengths and introduce medical cannabis-based medicines as a promising treatment option for patients

Dr Reddy’s numbers in line; launches in FY23 likely drivers: ICICI Direct

News | January 31, 2022

Dr Reddy’s numbers in line; launches in FY23 likely drivers: ICICI Direct

ICICI Direct analysis of Dr Reddy’s Q3FY22 results

Cipla has strong traction in India and the US: ICICI Direct

News | January 31, 2022

Cipla has strong traction in India and the US: ICICI Direct

ICICI Direct’s analysis of Cipla’s Q3FY22 results

Cipla’s Q3FY22 PAT at Rs 729 cr.

News | January 26, 2022

Cipla’s Q3FY22 PAT at Rs 729 cr.

Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.

Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22

News | January 21, 2022

Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22

Biocon has reported consolidated financial results for the period ended December 31, 2021

Lupin ties up with Foncoo of China

News | January 19, 2022

Lupin ties up with Foncoo of China

This is the company’s first partnership arrangement in China

Normalised quarter with impending margin pressure: ICICI Direct

News | January 13, 2022

Normalised quarter with impending margin pressure: ICICI Direct

ICICI Direct gives a preview on the earnings narrative for Q3FY22

Latest Stories

Zydus receives final approval from USFDA for Niacin Extended-Release Tablets USP

Vimta Labs posts Q4 FY25 PAT at Rs. 18.31 Cr

Sigachi Industries signs MoU with Respilon Group

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews

India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant

India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Dr. R. Ananthanarayanan CEO, Sajjan India

Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries

Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries

Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging